You searched for cancer.
Page 3 of 442 results
Recurrent and Refractory Cancer Treatment Program
The Recurrent and Refractory Cancer Treatment Program is dedicated to working with patients whose cancers have recurred or are not responding to treatments.
Physical Therapy During Cancer Treatment
CHOC provides physical therapy during and after cancer treatment to help with difficulty doing daily activities resulting from cancer treatment.
Outpatient Cancer Treatment Services
We strive to treat patients as much as possible on an outpatient basis so that they can focus on getting better in the comfort of their own homes and maintain as normal a lifestyle that their treatment will allow.
Cancer Diagnostic Tests
We are proud to be able to provide our oncology patients with everything they will need without having to leave CHOC.
CHOC Oncology Patient Ball
Experience an unforgettable night of fun and community for teen and young adult patients with cancer at the CHOC Oncology Patient Ball.
Oncology Clinical Trial: Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Clinical Trial Protocol # ALTE07C1 | Survivorship | Contact (714) 509-8646
How immunotherapy works to treat your child’s cancer
Dr. Ashley Plant, pediatric oncologist, discusses how the immune system and immunotherapy cancer treatment work together to treat your child’s cancer.
Treating Your Child’s Cancer with Precision Medicine
Dr. Ashley Plant, pediatric oncologist, discusses treating your child’s cancer with precision medicine, tailoring medical treatment to the individual genetic characteristics of each patient’s disease.
Understanding and Treating Recurrent and Refractory Cancers
Dr. Van Huynh, pediatric oncologist, discusses what it means when your child has recurrent or refractory cancer and the treatments available.
Oncology Clinical Trial: Childhood Cancer Survivor Study
Clinical Trial | Survivorship | Contact (714) 509-8646
When a Child Has Plastic Surgery After Cancer Treatment
Dr. Raj Vyas explains how cancer treatment can cause a physical defect that requires reconstructive surgery to repair.
Oncology Clinical Trial: Approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer.
Clinical Trial | Survivorship | Contact (714) 509-8646
Oncology Clinical Trial: Can Video Testimonials Benefit Adolescents with Cancer?
Clinical Trial | Adolescents and Young Adults, Supportive Care | Contact (714) 509-8646
Oncology Clinical Trial: Fertility Preservation in Women and Girls with Cancer
Clinical Trial | Adolescents and Young Adults, Fertility, Survivorship | Contact (714) 509-8646
Oncology Clinical Trial: Project – Every Child for Younger Patients With Cancer
Clinical Trial Protocol # APEC14B1 | Biology/Genomics, Registry | Contact (714) 509-8646
Breaking Barriers in Acute Lymphoblasic Luekemia (ALL)
This year, the conference, titled "Breaking Barriers in Acute Lymphoblastic Leukemia," focused, as the name implies, specifically on all aspects of acute lymphoblastic leukemia (ALL).
Torno, Lilibeth L. MD
Dr. Torno is a CHOC Specialist in pediatric oncology and the medical director of the After Cancer Treatment Survivorship (ACTS) Program.
Oncology Clinical Trial: A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Clinical Trial Protocol # MK3475-051/ADVL1621 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
ADVL1513, A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma
Clinical Trial Protocol # ADVL1513 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
AHOD1721/BMS CA209744 – Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after
Clinical Trial Protocol # AHOD1721 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
Clinical Trial Protocol # ADVL1621 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Kids and Melanoma
Orange County is one of the sunniest places in California, with hundreds of sun days per year. With that comes the need for proper protection.
Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Phase 1 Study of ABI-009 (nab-rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
Clinical Trial Protocol # ADVL1514 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646